MoonLake’s nanobody boosts all clinical endpoints in phase 3 psoriatic arthritis trial
MoonLake Immunotherapeutics announced positive phase 3 data for patients with psoriatic arthritis treated with its lead nanobody candidate, sonelokimab.
fiercebiotech · 1d ago
AbbVie shares pressured as Q2 I&I beat falls below investor expectations
AbbVie investors’ sky-high expectations led to a 4% share decline on Friday as the company reported more modest consensus beats than expected.
biospace · 11d ago
cAMPfield lands $180M to build gut disease drug
The biotech is advancing an anti-inflammatory drug that originated with vTv for inflammatory bowel diseases, leaning on a better side effect profile.
biopharma_dive · 1mo ago
Biogen adds more immune drugs in $1B buyout of secretive startup RayThera
The companies didn’t specify the drugs Biogen is acquiring in the deal, though patents RayThera secured provide important clues.
biopharma_dive · 1mo ago
Opinion: The podcast telling the stories behind Ambien, Ozempic, EpiPens, and other game-changing drugs
“We're basically not using our body as directed,” says "Drug Story" host Thomas Goetz.
stat · 3mo ago

brand

YUSIMRY

trade names

Amgevita, Amsparity, Cyltezo, Halimatoz, Hefiya, Hulio

generic

ADALIMUMAB-AQVH

MOA

12.1 Mechanism of Action Adalimumab products bind specifically to TNF-alpha and block its interaction with the p55 and p75 cell surface TNF receptors. Adalimumab products also lyse surface TNF expressing cells in vitro in the presence of complement. Adalimumab products do not bind or inactivate lymphotoxin (TNF-beta). TNF is a naturally occurring cytokine that is involved in normal inflammatory and immune responses. Elevated concentrations of TNF are found in the synovial fluid of patients with RA, JIA, PsA, and AS and play an important role in both the pathologic inflammation and the joint destruction that are hallmarks of these diseases. Increased concentrations of TNF are also found in psoriasis plaques. In Ps, treatment with YUSIMRY may reduce the epidermal thickness and infiltration of inflammatory cells. The relationship between these pharmacodynamic activities and the mechanism(s) by which adalimumab products exert their clinical effects is unknown. Adalimumab products also modulate biological responses that are induced or regulated by TNF, including changes in the concentrations of adhesion molecules responsible for leukocyte migration (ELAM-1, VCAM-1, and ICAM-1 with an IC 50 of 1-2 X 10 -10 M).

phase

marketed

Data sources

openFDA · ClinicalTrials.gov · OpenTargets

last refreshed 30m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

drug · antibody

save

YUSIMRY

Marketedupdated 3mo ago

by $COGT Cogent Biosciences, Inc.🔗 ChEMBL

Approved

community read0 votes

🐶 often sniffed alongside

top 8

Antibody drug with a maximum clinical stage of Approval (across all indications), with 14 approved and 20 investigational indications.

targets

Tumor necrosis factor

all catalysts(5)

approval · 5

YUSIMRY (ADALIMUMAB-AQVH) — FDA approval

YUSIMRY (ADALIMUMAB-AQVH) — FDA approval

YUSIMRY (ADALIMUMAB-AQVH) — FDA approval

YUSIMRY (ADALIMUMAB-AQVH) — FDA approval

YUSIMRY (ADALIMUMAB-AQVH) — FDA approval

YUSIMRY

→

News(5)

MoonLake’s nanobody boosts all clinical endpoints in phase 3 psoriatic arthritis trial
MoonLake Immunotherapeutics announced positive phase 3 data for patients with psoriatic arthritis treated with its lead nanobody candidate, sonelokimab.
fiercebiotech · 1d ago
AbbVie shares pressured as Q2 I&I beat falls below investor expectations
AbbVie investors’ sky-high expectations led to a 4% share decline on Friday as the company reported more modest consensus beats than expected.
biospace · 11d ago
cAMPfield lands $180M to build gut disease drug
The biotech is advancing an anti-inflammatory drug that originated with vTv for inflammatory bowel diseases, leaning on a better side effect profile.
biopharma_dive · 1mo ago
Biogen adds more immune drugs in $1B buyout of secretive startup RayThera
The companies didn’t specify the drugs Biogen is acquiring in the deal, though patents RayThera secured provide important clues.
biopharma_dive · 1mo ago
Opinion: The podcast telling the stories behind Ambien, Ozempic, EpiPens, and other game-changing drugs
“We're basically not using our body as directed,” says "Drug Story" host Thomas Goetz.
stat · 3mo ago

brand

YUSIMRY

trade names

Amgevita, Amsparity, Cyltezo, Halimatoz, Hefiya, Hulio

generic

ADALIMUMAB-AQVH

MOA

phase

marketed

Data sources

openFDA · ClinicalTrials.gov · OpenTargets

last refreshed 30m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

YUSIMRY

🐶 often sniffed alongside

targets

all catalysts(5)

News(5)

Report a data issue

comments(0)

YUSIMRY

🐶 often sniffed alongside

targets

all catalysts(5)

News(5)

Report a data issue

comments(0)